muSerum soluble Fas in Hodgkin's disease

Abstract

Abstract:Background: Hodgkin disease (HD) is a histologically defined B- cell neoplasm and it includes two distincttypes of disease, classical and nodular lymphocyte-predominant Hodgkin’s disease. Disruption of thephysiological balance between cell proliferation and apoptosis is a universal feature of all cancers.Apoptosis is caused by activation of the caspases through extrinsic and intrinsic pathways. Extrinsicpathway centers on TNF family, where the ligand will bind to the cell surface receptor to induceapoptosis. Fas receptor is a member of the TNF receptor superfamily. Fas family is constituted of thereceptor, ligand and soluble form. Soluble Fas will interfere with apoptosis by competing with Fasreceptor for binding to legend. The aim of this study is to measure the concentration of serum soluble Fasin Hodgkin’s disease patients and to determine the relation between it and certain clinical parameters andserum markers. Also to compare the concentration of serum sFas in HD and Non-Hodgkin’s lymphoma(NHL) patients.Patients & Methods: This study included 15 patients with Hodgkin's disease, 9 males and 6 females. Thepatients were interviewed for history and clinical examination and blood was collected for measurementof serum sFas concentration using ELISA technique. Hemoglobin (Hb) concentration, leucocytes andplatelets counts, peripheral blood smear, C-reactive protein (CRP) and lactate dehydrogenase (LDH) levelwere all performed using standard techniques.Results: This study revealed that the serum soluble Fas concentration was almost the same (p-value = 0.991) inboth HD patients (1996.9 ± 131) and normal controls (1993 ± 125.9). However, by comparing the resultsof this study with the high concentration results obtained for serum sFas in newly diagnosed NHLpatients (6475.9 ± 617) of another study, it revealed a highly significant difference (p-value < 0.0001)between the two groups.Conclusions: The serum Fas concentration differs significantly between HD and NHL patients but not withcontrol patients. Further studies including larger number of patients are recommended.